FY2024 EPS Estimates for uniQure Reduced by HC Wainwright

uniQure (NASDAQ:QURE) – Analysts at HC Wainwright cut their FY2024 earnings per share estimates for shares of uniQure in a research note issued on Monday, January 27th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings of ($4.17) per share for the year, down from their prior estimate of ($4.16). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.74) per share. HC Wainwright also issued estimates for uniQure’s Q4 2024 earnings at ($0.75) EPS, Q1 2025 earnings at ($0.66) EPS, Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.85) EPS, FY2025 earnings at ($2.99) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at $6.91 EPS and FY2028 earnings at $16.97 EPS.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%.

A number of other research analysts have also recently commented on the company. Stifel Nicolaus increased their price target on uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 16th. StockNews.com upgraded uniQure to a “sell” rating in a research report on Wednesday, December 11th. Royal Bank of Canada restated an “outperform” rating and set a $24.00 price target on shares of uniQure in a report on Tuesday, January 21st. Guggenheim reiterated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Finally, The Goldman Sachs Group boosted their target price on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $40.00.

uniQure Stock Performance

Shares of uniQure stock opened at $15.24 on Wednesday. The company’s 50 day moving average price is $13.31 and its two-hundred day moving average price is $8.84. The firm has a market capitalization of $742.80 million, a P/E ratio of -3.07 and a beta of 0.41. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.74% of the stock is owned by insiders.

Institutional Trading of uniQure

Several hedge funds have recently modified their holdings of QURE. abrdn plc grew its position in uniQure by 381.7% in the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after purchasing an additional 1,528,581 shares during the period. Franklin Resources Inc. bought a new position in shares of uniQure in the third quarter valued at $7,360,000. Point72 Asset Management L.P. grew its holdings in shares of uniQure by 336.1% during the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after buying an additional 752,889 shares during the last quarter. FMR LLC increased its position in shares of uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after acquiring an additional 346,274 shares in the last quarter. Finally, Privium Fund Management B.V. raised its holdings in shares of uniQure by 16.3% in the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after acquiring an additional 104,500 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.